

CLAIMS

1. A drug combination comprising a B-Raf inhibitor of formula (I), or a pharmaceutically acceptable salt thereof,




(I)

and a Mek 1/2 inhibitor which is a compound B, or a pharmaceutically acceptable salt thereof,




Compound B

for use in treatment of a patient suffering from melanoma, or use of a B-Raf inhibitor of formula (I), or a pharmaceutically acceptable salt thereof,



(I)

and a Mek 1/2 inhibitor which is a compound B, or a pharmaceutically acceptable salt thereof,



Compound B

in the preparation of a drug combination for the treatment of a patient suffering from melanoma,
wherein

(a) a therapeutically effective amount of a B-Raf inhibitor, or a pharmaceutically acceptable salt thereof is to be administered to the patient until the patient exhibits disease progression;

(b) detecting for a genetic alteration in one or more genes selected from the group consisting of BRAF, CRAF, MAP2K1, MAPK2, NRAS, KRAS HRAS and EGFR from an isolated tumor sample from the patient after disease progression; and

(c) a drug combination therapy comprising said compound of formula (I) and said Compound B is to be administered to a patient detected with at least one said genetic alteration.

2. The drug combination or use of claim 1, wherein the B-Raf inhibitor in step (a) is a compound of formula (I).

3. The drug combination or use of claim 1 or 2, wherein the gene is BRAF.

4. The drug combination or use of any one of claims 1-3, wherein the genetic alteration results from amplification of the one or more genes, mutations in the one or more genes, or loss of the one or more genes' activity.

5. The drug combination or use of any one of claims 1-4, wherein the genetic alteration results from a mutation in one or more genes.

6. The drug combination or use of claim 5, wherein the one or more genes is BRAF.

7. The drug combination or use of claim 6, wherein the mutation is a V600 mutation in BRAF.

8. The drug combination or use of claim 7, wherein the V600 mutation in BRAF is a V600E mutation or a V600K mutation.

9. The drug combination or use of claim 7, wherein the V600 mutation in BRAF is a V600E mutation.

10. The drug combination or use of any one of claims 1-9, wherein disease progression is evaluated using RECIST criteria.

11. The drug combination or use of any one of claims 1-10, wherein in step (a) the B-Raf inhibitor is to be administered as a monotherapy first.

12. The drug combination or use of any one of claims 1-11, wherein the B-Raf inhibitor in step (a) is to be administered continuously.

13. The drug combination or use of any one of claims 1-11, wherein the B-Raf inhibitor in step (a) is to be administered intermittently.

14. The drug combination or use of any one of claims 1-13, wherein the compound of formula (I) in step (c) is to be administered continuously.

15. The drug combination or use of any one of claims 1-13, wherein the compound of formula (I) in step (c) is to be administered intermittently.

16. The drug combination of any one of claims 1-11 or 13-15, wherein the B-Raf inhibitor in step (a) is to be administered orally.

17. The drug combination or use of any one of claims 1-13 or 15-16, wherein the compound of formula (I) and Compound B in step (c) are each to be administered orally.

18. The drug combination or use of any one of claims 1-17, wherein the B-Raf inhibitor in step (a) is to be administered at a dose of from 150 mg to 600 mg/day.

19. The drug combination or use of any one of claims 1-18, wherein the compound of formula (I) in step (c) is to be administered at a dose of from 150 mg to 600 mg/day.

20. The drug combination or use of any one of claims 1-19, wherein the compound of formula (I) in step (c) is to be administered at a dose of 450 mg/day.

21. The drug combination or use of any one of claims 1-20, wherein Compound B in step (c) is to be administered at a dose of from 15 mg to 60 mg twice daily.

22. The drug combination or use of any one of claims 1-21, wherein Compound B in step (c) is to be administered at a dose of 45 mg twice daily.

23. The drug combination or use of claim 21 or 22, wherein the two doses of Compound B are to be administered 12 hours apart.

24. The drug combination or use of any one of claims 1-23, wherein the compound of formula (I) and Compound B are to be administered during a 21 day cycle.

25. The drug combination or use of any one of claims 1-24, wherein the melanoma is a locally advanced or metastatic melanoma.

26. The drug combination or use of any one of claims 1-25, wherein the melanoma is an unresectable stage III melanoma or a stage IIIC to IV metastatic melanoma.

27. The drug combination or use of any one of claims 1-26, wherein prior to step (a), the patient is naïve to a BRAF inhibitor.